Adenosine A2A Receptor Agonists and Antagonists Protect Against Spinal Cord Injury
Author Information
Author(s): Paterniti Irene, Melani Alessia, Cipriani Sara, Corti Francesca, Mello Tommaso, Mazzon Emanuela, Esposito Emanuela, Bramanti Placido, Cuzzocrea Salvatore, Pedata Felicita
Primary Institution: Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Italy
Hypothesis
The main action mechanism of agonists and antagonists is at peripheral or central sites.
Conclusion
The A2A antagonist protects against spinal cord injury by acting on centrally located A2A receptors, likely reducing excitotoxicity.
Supporting Evidence
- Systemic treatment with SCH58261 improved neurological deficits up to 10 days after spinal cord injury.
- SCH58261 reduced levels of inflammatory markers such as TNF-α and Bax.
- Direct injection of SCH58261 into the spinal cord provided neuroprotection.
- Both A2A agonist and antagonist reduced expression of A2A receptors after spinal cord injury.
Takeaway
This study shows that a specific drug can help protect the spinal cord after an injury by working in the brain and spinal cord.
Methodology
Mice underwent spinal cord injury through extradural compression, followed by administration of A2A receptor agonists and antagonists.
Potential Biases
Potential bias in the interpretation of results due to the subjective nature of histological assessments.
Limitations
The study primarily focuses on mouse models, which may not fully replicate human spinal cord injury responses.
Participant Demographics
Male adult CD1 mice, weighing 25-30 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website